Takeda Pharmaceutical Down Nearly 9%, on Pace for Largest Percent Decrease Since October 2021 — Data Talk
Takeda Pharmaceutical Co. Ltd. Sponsored ADR (TAK) is currently at $13.24, down $1.26 or 8.71%
--Would be lowest close since Nov. 9, 2022, when it closed at $13.22
--On pace for largest percent decrease since Oct. 6, 2021, when it fell 11.01%
--Currently down three of the past four days
--Currently down two consecutive days; down 9.21% over this period
--Worst two day stretch since the two days ending Oct. 7, 2021, when it fell 10.63%
--Down 14.44% month-to-date; on pace for worst month since March 2018, when it fell 15.95%
--Down 15.15% year-to-date; on pace for worst year since 2021, when it fell 25.11%
--Down 56.73% from its all-time closing high of $30.59 on Jan. 26, 2018
--Up 1.51% from 52 weeks ago (Oct. 27, 2022), when it closed at $13.04
--Down 22.64% from its 52-week closing high of $17.11 on May 9, 2023
--Up 1.51% from its 52-week closing low of $13.04 on Oct. 27, 2022
--Traded as low as $13.23; lowest intraday level since Nov. 9, 2022, when it hit $13.20
--Down 8.76% at today's intraday low; largest intraday percent decrease since Oct. 6, 2021, when it fell as much as 12.25%
All data as of 12:23:38 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 26, 2023 12:43 ET (16:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Salesforce Earnings: Slowing Growth and Risk of More Disappointment Ahead
-
Chewy Earnings: Market Likes Repurchase Program and Profit Improvements
-
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett